[Evaluation of US contrast medium (LEVOVIST) to experimental liver cancer].
Enhancement of liver cancer on ultrasonography (US) by injection of new contrast medium (LEVOVIST) was performed in rats with 3'-methyl-4-dimethylaminoazobenzene-induced hepatic carcinoma. Echosignals of cancer nodules increased remarkably after the intrahepatic arterial injection of LEVOVIST (200, 300 mg/ml), and contrast enhancement was observed for at least 15 minutes. Furthermore, US after the intrahepatic arterial injection of LEVOVIST (200 mg/ml) can visualize small nodule, which was not recognizable on plain US. As a result of increased echosignals of normal liver parenchyma after the intra-portal injection of LEVOVIST (300 mg/ml), the cancer nodules were demonstrated as hypoechoic. These results indicate that this new contrast medium for sonography is effective in the diagnosis of liver cancer.
Ohkusa
A
A
Department of Radiology, Kinki University School of Medicine.
Yoshioka
H
H
Okafuji
T
T
Ishida
O
O
Fritz-Zieroth
B
B
D000818:Animals; D003287:Contrast Media / Q000592:standards*; D004341:Drug Evaluation; D007089:Image Enhancement; D008114:Liver Neoplasms, Experimental / Q000139:chemically induced / Q000000981:diagnostic imaging*; D008749:Methyldimethylaminoazobenzene; D051381:Rats; D014463:Ultrasonography
D003287:Contrast Media; D008749:Methyldimethylaminoazobenzene